Summary:
Northern California Research is seeking FDA approval for the medication Fasinumab. This medication is a monocolonal antibody (a type of protein) that blocks a substance called nerve growth factor (NGF). This study is being done to see if blocking NGF by using fasinumab can provide relief from pain caused by low back pain that is not relieved for NSAIDs, opioid therapy, and acetamenophine. The medication will be administered as an injection every 4 weeks and there will also be certain groups that receive medication IV every 8 weeks. This study is a 10 months long and includes 9 office visits throughout that time.
Qualified Participants Must:
• Be between 35-80 years or age
•
Have low back pain for the past 3 months
•
Take medication 4 days out of the week for low back pain
•
Have a pain score of 4 or greater on a daily basis
Qualified Participants May Receive:
All study related visits, tests, and study medication will be provided to the participant at no cost. Compensation for time and travel may also be provided.